Use of inhibitors of protein kinase C epsilon to treat pain
AssigneeThe Regents of the University of California
InventorsRobert O. Messing, Jon D. Levine
Life of this patent
Estimating the term…
Abstract
The role of the ε isozyme of protein kinase C (“PKCε”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKCε, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKCε and PKCε-independent analgesic agent are disclosed.
Claims26
A method of lessening pain, said method comprising:
- administering to a subject in need thereof, an effective amount of an inhibitor of the ε isozyme of protein kinase C (PKCε), wherein said effective amount is one that does not significantly inhibit the other isozymes of PKC.
A method of identifying a compound that modulates pain, said method comprising:
- selecting, as a test compound, an inhibitor of the ε isozyme of protein kinase C (PKCε), wherein the inhibitor significantly inhibits PKCε at a concentration at which the other isozymes of PKC are not significantly inhibited, and
- administering said test compound to a subject to determine whether pain is modulated.
A composition comprising an inhibitor of the ε isozyme of protein kinase C (PKCε), wherein the inhibitor significantly inhibits PKCε at a concentration at which the other isozymes of PKC are not significantly inhibited, and an analgesic agent, said analgesic agent having a mechanism of action other than inhibition of PKCε.
A composition comprising an inhibitor of the ε isozyme of protein kinase C (PKCε) and an analgesic agent, wherein said analgesic agent is selected from the group consisting of:
- local anesthetic and, an anticonvulsant.
A method of lessening pain, said method comprising:
- administering to a subject in need thereof, an effective amount of an inhibitor of the ε isozyme of protein kinase C (PKCε), wherein said method also comprises administering a compound selected from the group consisting of:
- an inhibitor of protein kinase A (PKA), an inhibitor of cAMP, a local anesthetic, and an anticonvulsant.
A method of lessening pain, said method comprising:
- administering to a subject in need thereof, an effective amount of an inhibitor of the ε isozyme of protein kinase C (PKCε), wherein said pain comprises neuropathic pain due to a condition selected from the group consisting of:
- causalgia, collagen vascular disease, trigeminal neuralgia, spinal cord injury, brain stem injury, thalamic pain syndrome, cancer, chronic alcoholism, stroke, abscess, demyelinating disease, herpes infection, and AIDS.
A method of lessening pain, said method comprising:
- administering to a subject in need thereof, an effective amount of an inhibitor of the ε isozyme of protein kinase C (PKCε), wherein said pain comprises neuropathic pain due to an agent selected from the group consisting of:
- trauma, surgery, amputation, and chemotherapy.
Dependencies are inferred from the claim text.